007570 — Ilyang Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩227bn
- KR₩335bn
- KR₩269bn
- 38
- 49
- 71
- 54
Annual cashflow statement for Ilyang Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | ARS/A | ARS/A | ARS/A | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 21,545 | 14,752 | 19,806 | -2,030 | 10,508 |
| Depreciation | |||||
| Non-Cash Items | 11,909 | 4,937 | -3,724 | 17,806 | 3,270 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 11,366 | 20,513 | -21,966 | -13,128 | -17,987 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 57,484 | 51,429 | 5,883 | 14,619 | 5,615 |
| Capital Expenditures | -24,622 | -14,679 | -3,958 | -6,832 | -40,623 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 3,462 | 8.24 | 28,121 | -4,683 | 3,448 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -21,160 | -14,671 | 24,163 | -11,516 | -37,175 |
| Financing Cash Flow Items | -142 | -31,524 | 184 | -22 | -0.559 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -30,961 | -36,632 | -31,996 | -6,978 | 32,240 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5,446 | 125 | -2,115 | -3,759 | 881 |